loading page

SHR2285, the first selectively oral FXIa inhibitor in China: Safety, tolerability, pharmacokinetics and pharmacodynamics combined with aspirin, clopidogrel or ticagrelor
  • +11
  • Tingting Ma,
  • Yanli Dong,
  • Lei Huang,
  • Yuanxun Yang,
  • Yan Geng,
  • Fei Fei,
  • Yun Jin,
  • Zeyu Yang,
  • Pinhao Xie,
  • Yu Zhao,
  • Hui Lin,
  • Xitong Ju,
  • Runbin Sun,
  • Juan Li
Tingting Ma
Nanjing University Medical School Affiliated Nanjing Drum Tower Hospital

Corresponding Author:[email protected]

Author Profile
Yanli Dong
Author Profile
Lei Huang
Nanjing University Medical School Affiliated Nanjing Drum Tower Hospital
Author Profile
Yuanxun Yang
Author Profile
Pinhao Xie
Author Profile
Hui Lin
Nanjing Drum Tower Hospital the Affiliated Hospital of Nanjing University Medical School
Author Profile
Runbin Sun
Nanjing Drum Tower Hospital
Author Profile


Aim: To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR2285, the first oral coagulation factor XIa (FXIa) inhibitor developed in China in combination with aspirin, clopidogrel or ticagrelor in healthy subjects. Methods: This study was a single-center, randomized, double-blind, placebo-controlled (only SHR2285) design. A total of 52 healthy subjects, 29 male and 23 female, were enrolled in this study. The subjects were divided into three groups: A, B and C, 16 subjects in group A (aspirin+clopidogrel+placebo or SHR2285 200mg bid (1:3)), 16 subjects in group B (aspirin+clopidogrel+placebo or SHR2285 300mg bid (1:3)) and 20 subjects in group C (aspirin+ticagrelor+placebo or SHR2285 300mg bid (2:3)), respectively. All groups were administered orally for 6 consecutive days. Results: 1. SHR2285 was well tolerated, and all adverse events were mild. There was no evidence of an increased risk of bleeding. 2. After 6 days of twice-daily administration, SHR2285 could reach a steady state. The half-life of SHR2285 was 13.9h, 14.5h and 13.8h respectively. 3. SHR2285 markedly inhibited FXI: C and prolonged APTT. The maximum inhibition rates of FXI: C in the three groups were 84.8%, 89.3% and 92.2% and the maximum prolongation time of APTT was 2.08-, 2.36-, and 2.26-fold, respectively. 4. The combination of aspirin, clopidogrel or ticagrelor had limited effect on the AUC of SHR2285. Conclusion: These data suggest that SHR2285, a potential oral FXIa inhibitor, is expected to become a novel, safe and effective anticoagulant.